These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 6850619)

  • 1. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Brundrett RB; Colvin M; Dray S
    Cancer Res; 1986 Jul; 46(7):3313-20. PubMed ID: 3486709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide.
    Tzai TS; Lin JS; Chow NH
    J Surg Res; 1996 Oct; 65(2):139-44. PubMed ID: 8903460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
    Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
    J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.